Edition:
United Kingdom

Athenex Inc (ATNX.OQ)

ATNX.OQ on NASDAQ Stock Exchange Global Select Market

16.70USD
17 Jan 2018
Change (% chg)

-- (--)
Prev Close
$16.70
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,408
52-wk High
$20.43
52-wk Low
$11.25

Chart for

About

Athenex, Inc. is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company's technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics. The Company... (more)

Overall

Beta: --
Market Cap(Mil.): $1,076.79
Shares Outstanding(Mil.): 57.06
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 85.75 16.58
EPS (TTM): -- -- --
ROI: -- 3.21 10.60
ROE: -- 4.54 14.19

BRIEF-Athenex Receives Positive Feedback From FDA On The Design Of Phase III Clinical Trial For Oraxol

* ATHENEX RECEIVES POSITIVE FEEDBACK FROM FDA ON THE DESIGN OF PHASE III CLINICAL TRIAL FOR ORAXOL

16 Jan 2018

BRIEF-Athenex Announces Chinese FDA Allowance Of Investigational New Drug Application Of Oraxol To Begin Clinical Trials

* ATHENEX ANNOUNCES CHINESE FDA ALLOWANCE OF INVESTIGATIONAL NEW DRUG APPLICATION OF ORAXOL TO BEGIN CLINICAL TRIALS

08 Jan 2018

BRIEF-Athenex Receives Promising Innovative Medicine Designation From The UK MHRA For Oraxol

* ATHENEX RECEIVES PROMISING INNOVATIVE MEDICINE DESIGNATION FROM THE UNITED KINGDOM MHRA FOR ORAXOL, AN INNOVATIVE ORAL FORM OF PACLITAXEL Source text for Eikon: Further company coverage:

27 Dec 2017

BRIEF-Athenex Inc ‍Initiates Oral Eribulin Investigational New Drug Development Program For Oncology Indications​

* ATHENEX INC - ‍INITIATION OF AN ORAL ERIBULIN INVESTIGATIONAL NEW DRUG DEVELOPMENT PROGRAM FOR ONCOLOGY INDICATIONS​ Source text for Eikon: Further company coverage:

15 Dec 2017

BRIEF-Almirall And Athenex Announces Partnership For Treatment Of Actinic Keratosis

* ALMIRALL AND ATHENEX ANNOUNCE STRATEGIC PARTNERSHIP FOR THE TREATMENT OF ACTINIC KERATOSIS

11 Dec 2017

BRIEF-Athenex Announces Planned Retirement Of Chief Financial Officer Nick Riehle

* ATHENEX ANNOUNCES PLANNED RETIREMENT OF CHIEF FINANCIAL OFFICER NICK RIEHLE

01 Dec 2017

BRIEF-Athenex announces Q3 revenue of $14 million

* Says ‍company raises full-year revenue guidance to range of $33 million - $35 million​

09 Nov 2017

BRIEF-Athenex announces positive recommendations from the ‍DSMB to continue the oraxol phase iii program

* Athenex announces positive recommendations from the Drug Safety Monitoring Board to continue the oraxol phase iii program

05 Oct 2017

BRIEF-Athenex Inc announces first patient recruitment in phase III clinical trials for KX-01 ointment

* Athenex, Inc. announces first patient recruitment in phase III clinical trials for KX-01 ointment for actinic keratosis

25 Sep 2017

BRIEF-Athenex Inc announces second quarter 2017 results

* Athenex Inc - ‍expect full-year revenues in range of $30 million to $34 million, inclusive of opportunity created by U.S. sodium bicarbonate shortage​ Source text for Eikon: Further company coverage:

14 Aug 2017

Earnings vs. Estimates